Overview
Cytomegalovirus (CMV) viremia refers to the presence of CMV in the bloodstream, often indicating active viral replication. It poses significant risks, particularly in immunocompromised individuals such as neonates and transplant recipients, due to potential severe complications from transfusion-transmitted CMV (TT-CMV). 1Diagnosis
Detection of CMV DNA in blood by PCR is the gold standard for diagnosing CMV viremia.
Serological tests can identify CMV-specific antibodies but do not differentiate active viremia from past infection.
Monitoring viral load through quantitative PCR can assess disease activity and response to treatment. 1Management
No specific antiviral treatment is universally recommended for asymptomatic CMV viremia in immunocompetent individuals.
For immunocompromised patients, first-line treatment often includes ganciclovir (5-10 mg/kg IV every 12 hours) or valganciclovir (900 mg PO daily).
Adjunctive treatments may include preemptive therapy in transplant recipients based on monitoring viral load post-transplant. 1Special Populations
Pregnancy: Specific guidelines for managing CMV viremia in pregnant women are not detailed in the provided abstracts.
Pediatrics: Neonates and infants are at high risk for severe CMV disease; CMV-safe blood products (leukoreduced and/or CMV-seronegative) are crucial. 1
Elderly: Limited specific recommendations; general principles of managing immunocompromised states apply.
Comorbidities: Transplant recipients and other immunocompromised patients require stringent monitoring and preemptive antiviral therapy to prevent complications. 1Key Recommendations
Universal leukoreduction of blood products should be implemented to mitigate TT-CMV risk. (Evidence: Strong 1)
Availability of CMV-seronegative blood products is recommended for institutions managing high-risk patients. (Evidence: Strong 1)
Preemptive antiviral therapy should be considered in transplant recipients based on monitoring for CMV viremia post-transplant. (Evidence: Moderate 1)References
1 Weisberg SP, Staley EM, Williams LA, Pham HP, Bachegowda LS, Cheng YH et al.. Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation. Archives of pathology & laboratory medicine 2017. link